Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 14, 2024
Data Byte
BridgeBio, Geron follow U.S. approvals with nods from EMA’s CHMP
November meeting highlights also include a pair of firsts for rare genetic diseases, and label expansions for eight approved drugs
BioCentury | Jun 10, 2020
Emerging Company Profile
Autobahn: fine-tuning thyroid agonism to remyelinate axons
Arch-incubated remyelination play Autobahn launches with $76M series B
BioCentury | Jun 8, 2017
Translation in Brief
Barrier gateways
BBB cell models open windows into two CNS disorders
Items per page:
1 - 4 of 4